BRCA1 and breast carcinoma: This study is based on the medical and health systems of China and the US, which will provide a more accurate reference for doctors in China and the US to use Talazoparib in the treatment of BRCA1/2 type advanced breast cancer patients in the future, and Chinese medical insurance will provide drug economic support for negotiations on Talazoparib treatment of advanced breast cancer.